CSPC Pharmaceutical Group Receives NMPA Approval for Two Antibody-Drug Conjugates
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received separate...
Company
CanSino Biologics Initiates Phase I/II Study for CS-2036 Polio Vaccine with Gates Foundation Support
CanSino Biologics (SHA: 688185, HKG: 6185) has announced the initiation of a Phase I/II study...
Innovent Biologics’ Taletrectinib Wins NMPA Approval for ROS1+ NSCLC Treatment
China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving marketing approval from the National Medical...
MicroPort Scientific Corp. Receives NMPA Approval for FireRaptor Coronary Atherectomy System
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...
Biopharma Company TransThera Sciences (Nanjing) Gets Green Light for HK IPO
On December 20, 2024, the China Securities Regulatory Commission confirmed the listing filing for TransThera...
YolTech Therapeutics’ YOLT-201 Advances in ATTR Treatment Clinical Trial
Shanghai, China, December 21, 2024 — YolTech Therapeutics today announced that its proprietary in vivo...
Wuhan Weike Medical Technology Secures Series C Funding to Boost Cardiovascular Innovation
Wuhan Weike Medical Technology Co., Ltd., known as “Weike Medical,” has officially announced the successful...
Sumitomo Pharma Expands Collaboration with Shanghai Pharmaceuticals for Prescription Drug Co-Marketing
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) has announced an expanded Contract Sales Organization (CSO)...
Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use
US-based Boston Scientific Corporation (NYSE: BSX) has announced that China’s National Medical Products Administration (NMPA)...
Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic
US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with...
Roche’s Prasinezumab Shows Promise in Phase IIb PADOVA Study for Early-Stage Parkinson’s Disease
Swiss pharmaceutical giant Roche (SWX: ROG) has published results from the Phase IIb PADOVA study...
Hainan Boao Lecheng and Sanofi Partner with Paris-Saclay Cancer Cluster for Advanced Cancer Treatments
The Hainan Boao Lecheng International Medical Tourism Pilot Zone, in collaboration with France’s major Sanofi’s...
Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its...
WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio
China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic...
MGI Tech Co., Ltd Partners with Sabin Group to Enhance Genetic Sequencing in Brazil
China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has entered into a strategic...
Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB
Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo...
BioArctic AB Secures Global Rights to PyroGlu-Aβ Antibody Program in BMS Deal
Sweden-based BioArctic AB (OTCMKTS: BRCTF) has announced a significant licensing agreement with US pharmaceutical giant...
Fangzhou Inc. Partners with BMS to Innovate Digital Medicine Platform
China-based Internet healthcare solutions provider Fangzhou Inc. (HKG: 6086) has entered into a partnership with...
Sanofi and Corxel Pharmaceuticals Partner for Aficamten in Greater China Rights
Global healthcare leader Sanofi (NASDAQ: SNY) and China-based Corxel Pharmaceuticals (CORXEL), formerly known as Ji...
HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies
China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has...